Search Results - "Nooij, M.A."

Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: A population-based study by Jansen-Landheer, M.L.E.A, Krijnen, P, Oostindiër, M.J, Kloosterman-Boele, W.M, Noordijk, E.M, Nooij, M.A, Steup, W.H, Taminiau, A.H.M, Vree, R, Hogendoorn, P.C.W, Tollenaar, R.A.E.M, Gelderblom, H

“…Abstract Aim The majority of clinicians, radiologists and pathologists have limited experience with soft tissue sarcomas. In 2004, national guidelines were…”
Get full text

Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study by Nooij, M.A., Whelan, J., Bramwell, V.H.C., Taminiau, A.T., Cannon, S., Hogendoorn, P.C.W., Pringle, J., Uscinska, B.M., Weeden, S., Kirkpatrick, A., Glabbeke, M.v., Craft, A.W.

“…There are limited data that define the role of chemotherapy in the treatment of high-grade spindle cell sarcomas of bone, other than osteosarcoma or malignant…”
Get full text

8056 Results of chemotherapy with etoposide, methotrexate, cyclophosphamide, actinomycine D and cisplatin (EMCAP) chemotherapy for high risk gestational trophoblastic neoplasia, a retrospective study by the Dutch Working Party on Trophoblastic Tumors by Ottevanger, P.B, Blanken, E.A, Groenewoud, J.M.M, van Hoesel, Q, Westermann, A.M, van Driel, W.J, van de Burg, M.E.L, Nooij, M.A, Verheijen, R.H.M

Get full text

Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials by Whelan, J.S., Jinks, R.C., McTiernan, A., Sydes, M.R., Hook, J.M., Trani, L., Uscinska, B., Bramwell, V., Lewis, I.J., Nooij, M.A., van Glabbeke, M., Grimer, R.J., Hogendoorn, P.C.W., Taminiau, A.H.M., Gelderblom, H.

“…Neoadjuvant chemotherapy improves outcome in osteosarcoma. Determination of optimum regimens for survival, toxicity and prognostic factors requires randomised…”
Get full text

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer by Rodenhuis, S., Bontenbal, M., van Hoesel, Q.G.C.M., Smit, W.M., Nooij, M.A., Voest, E.E., van der Wall, E., Hupperets, P., van Tinteren, H., Peterse, J.L., van de Vijver, M.J., de Vries, E.G.E.

“…Background: High-dose chemotherapy in the adjuvant treatment of breast cancer has been abandoned by many. Patients and methods: 885 patients with stage III…”
Get full text

Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: clinical outcomes and oncologists’ preferences by Nooij, M.A, de Haes, J.C.J.M, Beex, L.V.A.M, Wildiers, J, Klijn, J, Becquart, D, Jassem, J, Engelsman, E, Duchateau, L

“…The optimal duration of cytostatic treatment for metastatic breast cancer is still a matter of debate. Possible gain in the duration of remission has to be…”
Get full text

Survival of patients with ovarian cancer due to a mismatch repair defect by Crijnen, Th E M, Janssen-Heijnen, M L G, Gelderblom, H, Morreau, J, Nooij, M A, Kenter, G G, Vasen, H F A

“…Hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome) is characterized by the development of cancer of the colorectum, endometrium and other…”
Get full text

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients by Nieboer, P, de Vries, E G E, Mulder, N H, Rodenhuis, S, Bontenbal, M, van der Wall, E, van Hoesel, Q G, Smit, W M, Hupperets, P, Voest, E E, Nooij, M A, Boezen, H M, van der Graaf, W T A

“…Neutropenia following high-dose chemotherapy leads to a high incidence of infectious complications, of which central venous catheter-related infections…”
Get full text

Stability of patients' preferences for chemotherapy: the impact of experience by Jansen, S J, Kievit, J, Nooij, M A, Stiggelbout, A M

“…Studies have shown that utilities for a particular treatment, elicited by means of a hypothetical treatment scenario, may remain stable within the same…”
Get full text

Bleomycin, Methotrexate, and CCNU in Locally Advanced or Recurrent, Inoperable, Squamous-Cell Carcinoma of the Vulva: An EORTC Gynaecological Cancer Cooperative Group Study by Wagenaar, H.C., Colombo, N., Vergote, I., Hoctin-Boes, G., Zanetta, G., Pecorelli, S., Lacave, A.J., van Hoesel, Q., Cervantes, A., Bolis, G., Namer, M., Lhommé, C., Guastalla, J.P., Nooij, M.A., Poveda, A., Scotto di Palumbo, V., Vermorken, J.B.

“…Objectives. To investigate tumor response rate and treatment toxicity of a modified combination chemotherapy consisting of bleomycin (B), methotrexate (M), and…”
Get full text

Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients by Nooij, M.A, de Haes, J.C.J.M, Beex, L.V.A.M, Wildiers, J, Klijn, J, Becquart, D, Jassem, J, Engelsman, E, Duchateau, L

Get full text

High-dose chemotherapy in breast cancer. The Dutch trial by de Vries, E.G.E., Bontendal, M., Beex, L.V.A.M., van der Wall, E., Richel, D.J., Nooij, M.A., Voest, E., Hupperets, P., Westermann, A.M., Dalesio, O., Rodenhuis, S.

Get full text

CMF and mitoxantrone in elderly patients with advanced breast cancer. A randomized phase II study by Nooij, M.A., Steenland, E., Beex, L.V.A.M., van de Bos, B., Ruiter, L., Haes, J.C.J.M.

Get full text